A
2.50
0.06 (2.46%)
| Previous Close | 2.44 |
| Open | 2.49 |
| Volume | 84,125 |
| Avg. Volume (3M) | 390,998 |
| Market Cap | 102,711,752 |
| Price / Book | 7.32 |
| 52 Weeks Range | |
| Earnings Date | 23 Sep 2025 - 29 Sep 2025 |
| Diluted EPS (TTM) | -0.250 |
| Current Ratio (MRQ) | 25.29 |
| Operating Cash Flow (TTM) | -6.75 M |
| Levered Free Cash Flow (TTM) | -4.47 M |
| Return on Assets (TTM) | -51.45% |
| Return on Equity (TTM) | -83.37% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Anebulo Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
-2.1
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -2.13 |
|
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 40.54% |
| % Held by Institutions | 55.05% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Sep 2025 | Announcement | Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates |
| 25 Sep 2025 | Announcement | Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity |
| 12 Sep 2025 | Announcement | Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives |
| 23 Jul 2025 | Announcement | Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |